Search

Fibralign Announces Enrollment Initiated for Stanford-led Clinical Trial for Breast Cancer-Related L

Fibralign Corporation announced that Stanford University has started enrollment in its investigator-led clinical study to evaluate the efficacy of a new surgical device for treating secondary lymphedema. ​ The trial will evaluate the effectiveness of Fibralign’s BioBridge® Collagen Matrix in supporting and guiding lymphatic repair in patients with acquired lymphedema of upper and lower extremities. Stanford plans to enroll at least 36 patients into the study, which will utilize BioBridge as an adjunctive interventional device for vascularized lymph node transfer (VLNT) surgery. VLNT is an increasingly practiced micro-surgical procedure for patients with lymphedema, in which an auxiliary l

WHO WE ARE

Fibralign Corporation is a developer of advanced therapeutic devices that utilizes Nanoweave ®, a proprietary scaffolding technology for addressing unmet medical needs.

Read More >

QUICK LINKS
GET IN TOUCH